JOP20240256A1 - بروتينات اندماج hmpv مُستقرة في صورة ما قبل الإندماج - Google Patents

بروتينات اندماج hmpv مُستقرة في صورة ما قبل الإندماج

Info

Publication number
JOP20240256A1
JOP20240256A1 JOJO/P/2024/0256A JOP20240256A JOP20240256A1 JO P20240256 A1 JOP20240256 A1 JO P20240256A1 JO P20240256 A JOP20240256 A JO P20240256A JO P20240256 A1 JOP20240256 A1 JO P20240256A1
Authority
JO
Jordan
Prior art keywords
hmpv
fusion
stable
proteins
fusion proteins
Prior art date
Application number
JOJO/P/2024/0256A
Other languages
Arabic (ar)
English (en)
Inventor
Johannes Petrus Maria Langedijk
Ritschel Tina
Johannes Gerardus BAKKERS Mark
Juraszek Jaroslaw
Original Assignee
Msd Int Business Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Int Business Gmbh filed Critical Msd Int Business Gmbh
Publication of JOP20240256A1 publication Critical patent/JOP20240256A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JOJO/P/2024/0256A 2022-05-12 2024-11-11 بروتينات اندماج hmpv مُستقرة في صورة ما قبل الإندماج JOP20240256A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22173131 2022-05-12
PCT/EP2023/062652 WO2023217988A1 (en) 2022-05-12 2023-05-11 Stabilized pre-fusion hmpv fusion proteins

Publications (1)

Publication Number Publication Date
JOP20240256A1 true JOP20240256A1 (ar) 2024-11-11

Family

ID=81653543

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2024/0256A JOP20240256A1 (ar) 2022-05-12 2024-11-11 بروتينات اندماج hmpv مُستقرة في صورة ما قبل الإندماج

Country Status (16)

Country Link
EP (1) EP4522209A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025521082A (cg-RX-API-DMAC7.html)
KR (1) KR20250010642A (cg-RX-API-DMAC7.html)
CN (1) CN119562826A (cg-RX-API-DMAC7.html)
AU (1) AU2023269241A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253332A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024003418A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024015386A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240493A (cg-RX-API-DMAC7.html)
DO (1) DOP2024000230A (cg-RX-API-DMAC7.html)
GE (1) GEAP202516650A (cg-RX-API-DMAC7.html)
IL (1) IL316911A (cg-RX-API-DMAC7.html)
JO (1) JOP20240256A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024013959A (cg-RX-API-DMAC7.html)
PE (1) PE20251395A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023217988A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120548194A (zh) 2023-01-18 2025-08-26 辉瑞公司 针对呼吸道疾病的疫苗
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025144636A1 (en) * 2023-12-26 2025-07-03 The Scripps Research Institute ENGINEERED hMPV F PROTEIN IMMUNOGENS AND RELATED VACCINES
WO2025163460A2 (en) * 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
WO2003104467A1 (en) 2002-04-25 2003-12-18 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
ES2993107T3 (en) 2016-10-17 2024-12-23 Janssen Pharmaceuticals Inc Recombinant virus replicon systems and uses thereof
JP7788787B2 (ja) 2016-12-05 2025-12-19 ヤンセン ファーマシューティカルズ，インコーポレーテッド 遺伝子発現増強のための組成物および方法
CN118359709A (zh) * 2019-05-21 2024-07-19 佐治亚大学研究基金会有限公司 结合人类偏肺病毒融合蛋白的抗体及其用途
IL320367A (en) * 2020-10-09 2025-06-01 Univ Texas Prefusion-stabilized hmpv f proteins

Also Published As

Publication number Publication date
KR20250010642A (ko) 2025-01-21
DOP2024000230A (es) 2025-02-16
CN119562826A (zh) 2025-03-04
PE20251395A1 (es) 2025-05-22
WO2023217988A1 (en) 2023-11-16
CA3253332A1 (en) 2023-11-16
JP2025521082A (ja) 2025-07-08
AU2023269241A1 (en) 2024-11-21
IL316911A (en) 2025-01-01
CL2024003418A1 (es) 2025-08-01
CR20240493A (es) 2025-01-29
EP4522209A1 (en) 2025-03-19
GEAP202516650A (en) 2025-03-10
MX2024013959A (es) 2025-02-10
CO2024015386A2 (es) 2024-11-28

Similar Documents

Publication Publication Date Title
GEAP202516650A (en) Stabilized pre-fusion hmpv fusion proteins
MX2021014863A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
SA520411173B1 (ar) Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137
MX2019003298A (es) Proteinas de union recombinantes y sus usos.
MX2020012350A (es) Anticuerpos anti-cd63, conjugados y usos de estos.
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
GT201000148A (es) Anticuerpos antimesotelina y usos de los mismos
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
UY31533A1 (es) Moleculas de enlace al receptor humano ox40
MX2017009153A (es) Proteinas de fusion de citoquinas.
CR20110245A (es) Mutantes fgf21 y uso de los mismos.
MX388739B (es) Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso.
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
PH12013502234A1 (en) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
ECSP088262A (es) Proteínas de fusión de albúmina
MX389093B (es) Composiciones y metodos para la glicosilacion de proteinas.
AR115695A1 (es) Moléculas proteicas multifuncionales que comprenden decorina y uso de estas
MX2023011629A (es) Proteinas piv3 f prefusion estabilizadas.
DE602007008360D1 (de) Aviäre telomerase reverse transkriptase
EA201691691A1 (ru) Белки слияния tatk-cdkl5, их композиции, составы и применение
MX2024005649A (es) Proteinas quimericas basadas en sirp1a y cd40l.
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
MX2019002321A (es) Identificación de mutaciones en variantes de opsina de canal con sensibilidad a la luz mejorada y métodos de uso de estas.
AR069958A1 (es) Metodo para producir una proteina heterologa de interes